Roche Archives

Roche announces Xofluza approval and new Elecsys IGRA SARS-CoV-2 test

News and Trends 15 Aug 2022

Roche announces influenza drug approval and new COVID test

Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years of age who have been symptomatic for no more than 48 hours. This marks […]

August 15, 2022 - 6 minutesmins - By Jim Cornall

multiple sclerosis novartis roche ema approval

News and Trends 27 Apr 2021

EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls

While the EU saw rapid-fire approvals in the multiple sclerosis space last month, the innovations centered mostly on improving existing approaches. Which areas of multiple sclerosis treatment need more options? At the end of March, the EMA made key decisions on three treatments for multiple sclerosis (MS), a chronic neurodegenerative disease affecting 2.5 million people […]

April 27, 2021 - 6 minutesmins - By Jonathan Smith

News and Trends 25 Sep 2020

Roche Confirms Pharma Appetite for Inflammatory Disease Treatments

Roche’s acquisition of the Irish biotech Inflazome is a vote of confidence for emerging inflammatory disease drugs. How could other companies in the field benefit from this takeover? The inflammation process is essential for our survival, as it helps the body to clear up damage after injury. However, uncontrolled inflammation can also harm us, causing […]

September 25, 2020 - 4 minutesmins - By Jonathan Smith

News and Trends 31 Oct 2019

European Project Launches to Tailor Autoimmune Disease Treatments

Public and private organizations across Europe will pool their resources in an €80M project to discover biomarkers that can predict which patients will respond best to treatments for autoimmune diseases. The project is called Taxonomy, Treatments, Targets and Remission, or 3TR for short, and is funded by the EU’s Innovative Medicines Initiative for the next […]

October 31, 2019 - 2 minutesmins - By Jonathan Smith

Interview 23 May 2019

Why Clinical Trial Design Can Make or Break Your Company

Andreas Wallnöfer spent over 20 years working on drug development at Roche before moving to BioMedPartners to apply his expertise to biotech investment. At our recent Labiotech Refresh event in Zurich, he explained why good clinical trial design can be key to a biotech’s success. Wallnöfer was one of the pioneers of ‘proof of concept’ […]

May 23, 2019 - 7 minutesmins - By Helen Albert

News and Trends 7 Jan 2019

AI Drug Discovery Company Raises €23M and Signs with Roche

Oxford-based Exscientia has closed a €23M ($26M) Series B round and announced a partnership with Roche worth up to €60M. Exscientia has developed an artificial intelligence platform to boost drug discovery in pharma and biotech. “We can reduce at least 4- to 5-fold the time and cost of drug discovery as compared to the industry […]

January 7, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

In Depth 9 Apr 2018

Are PD-1 and PD-L1 Checkpoint Inhibitors As Good As We Thought?

Checkpoint inhibitors, especially those targeting PD-1 and PD-L1, are exploding in popularity. But how much of it is hype? The pipelines of biotech and pharma are filling up with combination therapies for anti-PD-1 and PD-L1 antibodies. According to the Cancer Research Institute, there are now over 1,500 clinical trials testing the popular checkpoint inhibitors, a dramatical increase […]

April 9, 2018 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 Mar 2018

Danish Biotech Starts Phase III Atopic Dermatitis Trial With Failed Asthma Treatment

Danish biotech LEO Pharma started a Phase III trial in atopic dermatitis with an antibody that AstraZeneca dropped after failing two Phase III trials in asthma. LEO Pharma is taking over the development of the antibody tralokinumab from AstraZeneca to treat atopic dermatitis after the drug failed multiple Phase III studies for treating asthma. In […]

March 5, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 28 Feb 2018

Like Finding a Needle in a Haystack: How Are Biotechs Fighting Rare Diseases?

Rare diseases affect fewer than 1 in 2,000 people in Europe and less than 200,000 Americans at any given time. A lack of financial incentive has put pharma off but biotechs are keen to step in and develop treatments and cures. Over 6,000 rare diseases affect up to 30 million people in the EU alone, which highlights […]

February 28, 2018 - 8 minutesmins - By Alex Dale

News and Trends 22 Jan 2018

Abcam Will Start Selling Over 700 Antibodies from Roche

Abcam and Roche have entered an agreement that will let Abcam sell 760 new antibodies to researchers worldwide through its online platform. Inspired by Amazon, Abcam has become one of Europe’s biggest biotechs by building a platform to make it easier for researchers to order the antibodies they need for their experiments. A new deal with […]

January 22, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Dec 2017

Actelion Spin Out and Roche Join Forces to Develop Cancer Immunotherapies

Idorsia and Roche have agreed on a research collaboration, with the big pharma getting exclusive rights to develop and license resultant cancer immunotherapy drugs. Idorsia was formed out of J&J’s acquisition of Actelion for €27.9B at the beginning of the year. The spin out, led by Jean-Paul and Martine Clozel, kept hold of Actelion’s drug discovery and early […]

December 20, 2017 - 2 minutesmins - By Alex Dale

News and Trends 19 Dec 2017

Belgian Biotech and Roche Take on Neurological and Developmental Disorders

Confo Therapeutics has joined forces with Roche to develop new small molecule agonists of a G-protein coupled receptor to treat neurological and developmental disorders. Confo Therapeutics is developing a pipeline of G-protein coupled receptor (GPCR)-targeting drugs to address an unmet medical needs. The biotech spun out from the Vrije Universiteit Brussel in 2015 with the backing of […]

December 19, 2017 - 2 minutesmins - By Alex Dale

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us